Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)

Kukuła, Krzysztof; Chojnowska, Lidia; Dąbrowski, M; Witkowski, Adam; Chmielak, Zbigniew; Skwarek, Mirosław; Kądziela, Jacek; Teresińska, Anna; Małecki, Maciej; Janík, P.; Lewandowski, Zbigniew; Kłopotowski, Mariusz; Wnuk, Jacek; Rużyłło, Witold

doi:10.1016/j.ahj.2010.11.023

Cited by 87 publications

(47 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The assessment of therapeutic outcome after gene therapy clinical trials usually includes exercise stress testing to estimate functional capacity, echocardiography, nuclear scanning, computed tomography, magnetic resonance imaging, and cardiac catheterization [22, 28, 29, 31, 37]. Significant improvement in angina symptoms and exercise tolerance tests were found in many trials [10, 11, 21, 25, 32, 37, 38].…”

Section: Clinical Trials In Cardiac Surgerymentioning

confidence: 99%

Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives

Katz

Fargnoli

Kendle

et al. 2016

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

The concept of gene therapy was introduced in the 1970s after the development of recombinant DNA technology. Despite the initial great expectations, this field experienced early setbacks. Recent years have seen a revival of clinical programs of gene therapy in different fields of medicine. There are many promising targets for genetic therapy as an adjunct to cardiac surgery. The first positive long-term results were published for adenoviral administration of vascular endothelial growth factor with coronary artery bypass grafting. In this review we analyze the past, present, and future of gene therapy in cardiac surgery. The articles discussed were collected through PubMed and from author experience. The clinical trials referenced were found through the Wiley clinical trial database (http://www.wiley.com/legacy/wileychi/genmed/clinical/) as well as the National Institutes of Health clinical trial database (Clinicaltrials.gov).

show abstract

Section: Clinical Trials In Cardiac Surgerymentioning

confidence: 99%

Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives

Katz

Fargnoli

Kendle

et al. 2016

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Again in this study, no increase in cardiac perfusion was observed in the treated patients, despite marginal, clinical benefit. 35 Finally, a double-blind, placebo-controlled study entailing intramuscular injection of a VEGF-A 165 plasmid to patients with peripheral arterial disease also failed to meet its primary end point (amputation), despite showing objective (reduction of skin ulcers) and subjective (decreased pain) improvements in the treated patients. 36 To improve efficacy of therapeutic angiogenesis based on the VEGF-A gene for patients with PAD or CAD, an innovative possibility, alternative to angiogenic factor cDNA delivery, is to activate expression of the endogenous gene using zinc-finger proteins (ZFP) targeting transcriptional activators to the gene promoter.…”

Section: Clinical Use Of Vegfmentioning

confidence: 99%

VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond

2012

View full text Add to dashboard Cite

“…A key therapeutic strategy for AS is the promotion of angiogenesis. Previous studies have used various strategies to induce angiogenesis, including the delivery of VEGF (21), viral vectors (22)(23)(24) or plasmids (25,26); however, few have shown success, which may be due to the fact that the molecular mechanisms underlying angiogenesis are largely unknown. Using proliferation, migration and tube formation assays, the present study demonstrated that ox-LDL impaired angiogenesis by HUVECs in vitro.…”

Section: Discussionmentioning

confidence: 99%

Oxidized low-density lipoprotein decreases VEGFR2 expression in HUVECs and impairs angiogenesis

Zhang

2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Atherosclerosis (AS), which is triggered by endothelial cell injury, evolves into a chronic inflammatory disease. Oxidized low-density lipoprotein (ox-LDL) is an important risk factor for the development of atherosclerosis; ox-LDL induces atherosclerotic plaque formation via scavenging receptors. The present study used ox-LDL-treated human umbilical vein endothelial cells (HUVECs) to investigate the effect of ox-LDL on angiogenesis. ox-LDL decreased HUVEC proliferation by MTT, induced apoptosis by Annexin V-fluorescein isothiocyanate (FITC) staining and markedly suppressed HUVEC tube formation by the Matrigel assay in a dose-dependent manner. Angiogenesis has been correlated with monocyte invasion, plaque instability and atherosclerotic lesion formation. In addition, ox-LDL induced the overproduction of reactive oxygen species using DCFH-DA staining and increased caspase-3 activity. Vascular endothelial growth factor receptor 2 (VEGFR2) were detected by quantitative polymerase chain reaction and western blot analysis and has previously been observed to have a key role in angiogenesis. Furthermore, the present study demonstrated that the abundance of VEGFR2 was decreased in ox-LDL-treated HUVECs. These results suggested that ox-LDL impairs angiogenesis via VEGFR2 degradation, thus suggesting that VEGFR2 may be involved in adaptation to oxidative stress and AS.

show abstract

Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)

Cited by 87 publications

References 25 publications

Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives

Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives

VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond

Oxidized low-density lipoprotein decreases VEGFR2 expression in HUVECs and impairs angiogenesis

Contact Info

Product

Resources

About